Anaemetro I.V. Infusion 500mg Drug Use Investigation

Brief Title

Anaemetro I.V. Infusion 500mg Drug Use Investigation

Official Title

METRONIDAZOLE IV DRUG USE INVESTIGATION

Brief Summary

      Secondary Data Collection Study; safety and effectiveness of Anaemetro under Japanese medical
      practice
    



Study Type

Observational


Primary Outcome

Number of Participants With Adverse Drug Reaction (ADR)

Secondary Outcome

 Clinical Response Rate

Condition

Anaerobic Infection



Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

107

Start Date

July 2015

Completion Date

August 2017

Primary Completion Date

August 2017

Eligibility Criteria

        Inclusion Criteria:

          -  Patients who have not used metronidazole (injection) in the past, and have been given
             this drug for treatment of anaerobic infection, infectious enterocolitis, or amebic
             dysentery. Patients who have used metronidazole (oral agent and vaginal tablet) in the
             past are eligible, and should not be excluded from this study.

        Exclusion Criteria:

          -  No exclusion criteria are set out in this study.
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

Pfizer CT.gov Call Center, , 



Administrative Informations


NCT ID

NCT03491228

Organization ID

A6831007


Responsible Party

Sponsor

Study Sponsor

Pfizer


Study Sponsor

Pfizer CT.gov Call Center, Study Director, Pfizer


Verification Date

December 2018